Response: Suhr OB: commentary to Isabel Conceição et al. early diagnosis through targeted follow-up of identified carriers of TTR gene mutations

"Response: Suhr OB: commentary to Isabel Conceição et al. early diagnosis through targeted follow-up of identified carriers of TTR gene mutations." Amyloid, 26(4), pp. 248–249

Disclosure statement

I. Conceição received financial support from Alnylam Pharmaceuticals, IONIS Pharmaceuticals, and Pfizer, and serves on the THAOS scientific advisory board. Medical writing support was provided by Synergy Medical Communications UK and unconditional financial support was funded by Pfizer. The author was not paid for their work developing the manuscript and the views and opinions expressed are solely those of the author.